Nkarta price target raised to $16 from $15 at Canaccord

Canaccord raised the firm’s price target on Nkarta to $16 from $15 and keeps a Buy rating on the shares. The firm noted Nkarta has had a string of new developments over the past several days, including 4Q23 results, deprioritization of NKX101, publication of incremental new data from cy-alone lymphodepletion and B cell reconstitution after NKX019, and finally, pricing of a $240M public offering that will support NKX019’s development for autoimmune indications.